A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265

Hoffmann-La Roche65 enrolled

Overview

This multicenter, prospective, observational study will evaluate the one-year outcomes in HBeAg positive chronic hepatitis B patients who had received Pegasys (peginterferon alfa-2a) in Arm A of study ML22265. Data will be collected from each patient for up to one year post-therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatitis B, Chronic

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who were randomized to study Arm A of ML22265 and were treated and completed follow-up in the study, regardless of treatment response at any time point Exclusion Criteria: * Patients unwilling to provide informed consent or abide by the requirements of the study

Locations (5)

Unnamed facility

Changsha, China

Unnamed facility

Fuzhou, China

Unnamed facility

Guangzhou, China

Unnamed facility

Wuhan, China

Unnamed facility

Xi'an, China

Outcomes

Primary Outcomes

Duration of response (HBeAg seroconversion/HBV DNA reduction/HBsAg loss/seroconversion) after end of treatment

Time frame: 1 year

Secondary Outcomes

Correlation of duration of response with on-treatment response (HBeAg/HBV DNA/HBsAg/ALT)

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.